Sage Announces Results of FDA Breakthrough Therapy Meeting – ISPE Boston
Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status - Elena Tomaselli Muensterman, Yijia Luo, Jonathon M. Parker, 2019
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration-CliniExpert
Sage Therapeutics Could Be In For A Depressing FDA Review (NASDAQ:SAGE) | Seeking Alpha
FDA Provides Expedited Path Forward For Sage's Depression Treatment SAGE-217 | BioSpace
Biogen signs deal with Sage to develop depression, tremor therapies
Sage Therapeutics stock rockets 73% on hopes for breakthrough depression drug - MarketWatch
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders | Business Wire
Zulresso: the world's first post-partum depression drug - Pharmaceutical Technology
Biogen signs $1.5bn depression drug deal with Sage Therapeutics
Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha
Zuranolone: Treatment Of Major Depression (MDD) And Postpartum Depression (PDD)! - Industry news - News - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd
Sage surges after depression drug gets rapid path to approval - PMLiVE
Sage Therapeutics Gets FDA Breakthrough Therapy Designation for Major Depressive Disorder Drug - Equities News
Biogen and Sage Therapeutics in Global Collaboration – ISPE Boston
Schematic model for the initial cellular target sites of rapid-acting... | Download Scientific Diagram
Sage Therapeutics and Biogen pursue FDA approval for zuranolone
Sage Therapeutics Looks to File NDA for Postpartum Depression Treatment Later This Year | BioSpace
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
SY Investing on X: "$SAGE (-62% PM) announced pivotal Ph 3 MOUNTAIN results of SAGE-217 in MDD. Study didn't meet primary endpoint. #Fail SAGE-217 showed mean reduction of 12.6 in HAM-D total
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
Sage Therapeutics' SAGE-217 fails in late-stage depression trial
Rx Product News: April 2023
